Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an option exercise-and-sale transaction in company stock. She exercised employee stock options to acquire a total of 11,008 shares of common stock at exercise prices of $8.72 and $1.86 per share, then sold 11,008 shares in an open-market sale at a weighted average price of $23.5616 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 13,579 shares of common stock and retains an employee stock option covering 128,611 shares at an exercise price of $8.72 per share, expiring on February 12, 2034.
NRIX report: Christine Ring filed a Form 144 to sell 11,008 shares via exercise of stock options and related cash proceeds. The filing also lists prior 10b5-1 sales on ranging from 4/30/2026 to 6/25/2026 totaling multiple transactions with disclosed share counts and gross proceeds.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen executed an open-market sale of 5,394 shares of Common Stock at $20.00 per share. The transaction was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than timed discretionarily. Following this sale, Hansen holds 115,005 shares directly, so the filing reflects a relatively small, planned reduction in her overall position.
Nurix Therapeutics Chief Legal Officer Christine Ring exercised stock options and sold the resulting shares in a pre-planned trade. On the reported date, she exercised options for 28,935 shares of common stock at strike prices of $8.72 and $7.26 per share and sold 28,935 shares in open-market transactions at a weighted average price of $20.0624 per share, pursuant to a Rule 10b5-1 trading plan. Following these transactions, the filing reports that she holds 13,579 shares of common stock directly and continues to hold employee stock options, including 134,398 options with a $8.72 exercise price expiring in 2034.
Christine Ring reported the resale of 28,935 shares of Common Stock under Rule 144. The filing lists 28,935 shares as securities to be sold via exercise of stock options for cash. The notice also itemizes recent 10b5-1 sales during April–June 2026 with per-trade share counts and proceeds.
NRIX notice of proposed sale of Common Stock restricted units. The filing lists 5,394 Restricted Stock Units authorized for sale with an effective date of 04/30/2026. It also reports 3,214 Common shares sold during the prior three months on 04/30/2026.
Nurix Therapeutics reported updated Phase 1a/1b clinical data for its oral BTK degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug was generally well tolerated across 142 treated patients, including 86 at the 600 mg once-daily recommended Phase 2 dose, with no dose-limiting toxicities and no treatment-related Grade 5 adverse events.
In the Phase 1a cohort of 48 heavily pretreated patients, the objective response rate was 83.0% among 47 evaluable patients, with a median progression-free survival of 22.1 months and responses seen in high-risk subgroups. Earlier-line Phase 1b cohorts showed objective response rates of 92.9% in BTK inhibitor–treated, BCL2 inhibitor–naïve patients and 84.2% in BTK inhibitor–naïve and treatment-naïve patients, with most patients remaining on treatment at the data cutoff.
Nurix Therapeutics entered a global license and collaboration agreement with Roche for bexobrutideg (NX-5948), an investigational oral BTK degrader for cancers and immune diseases. Roche will pay Nurix a $700 million upfront and up to $2.3 billion in potential development, regulatory, and sales milestones.
The partners will co-develop and co-commercialize bexobrutideg in the U.S., sharing development costs 40% Nurix and 60% Roche and splitting U.S. profits and losses 50/50. Outside the U.S., Roche will lead commercialization while Nurix receives tiered royalties from the low teens to the high teens. The deal becomes effective after required antitrust clearances.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock. She sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan, with sale prices ranging from $16.35 to $17.10. In a related move, she exercised employee stock options covering 3,422 shares at an exercise price of $1.86 per share, converting them into common stock. Following these transactions, she directly holds 13,579 shares of common stock and 5,221 employee stock options.
Christine Ring submitted a Form 144 notice relating to sales of Common Stock. The filing lists multiple 10b5-1 sales executed in April–May 2026, with individual transactions such as 05/04/2026: 3,368 shares ($57,118.25) and 05/01/2026: 5,394 shares ($90,406.68).
The filing also lists securities acquired earlier by means of Restricted Stock Units (678 shares, 05/02/2022), an Employee Stock Purchase Plan (4,048 shares, 08/11/2020), and previously exercised options (3,422 shares, 10/01/2019), each shown with its grant/acquisition date.